Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

BACKGROUND: HIV antiretroviral therapy (ART) is often managed without routine laboratory monitoring in Africa; however, the effect of this approach is unknown. This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term e...

Full description

Bibliographic Details
Main Authors:	Mugyenyi, P, Walker, A, Hakim, J, Munderi, P, Gibb, D, Kityo, C, Reid, A, Grosskurth, H, Darbyshire, J, Ssali, F, Bray, D, Katabira, E, Babiker, A, Gilks, C, Kabuye, G, Nsibambi, D, Kasirye, R, Zalwango, E, Nakazibwe, M, Kikaire, B, Nassuna, G, Massa, R, Fadhiru, K
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
by: Ssali, F, et al.
Published: (2006)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
by: Munderi, P, et al.
Published: (2010)

DART and laboratory monitoring of HIV treatment Reply
by: Walker, A, et al.
Published: (2010)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
by: Kikaire, B, et al.
Published: (2007)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
by: Gilks, C, et al.
Published: (2013)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
by: Munderi, P, et al.
Published: (2011)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
by: Muyingo, S, et al.
Published: (2008)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
by: Lara, A, et al.
Published: (2012)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
by: Stöhr, W, et al.
Published: (2011)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
by: Gomo, Z, et al.
Published: (2014)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
by: Gibb, D, et al.
Published: (2012)

CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.
by: Serwanga, J, et al.
Published: (2011)

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
by: Ford, D, et al.
Published: (2015)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
by: Kityo, C, et al.
Published: (2014)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models
by: Ford, D, et al.
Published: (2015)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
by: Ross, LL, et al.
Published: (2019)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
by: Reid, A, et al.
Published: (2008)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
by: Kityo, C, et al.
Published: (2010)

Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.
by: Stöhr, W, et al.
Published: (2008)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
by: Gilks, C, et al.
Published: (2012)

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
by: Ndembi, N, et al.
Published: (2010)

Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre (JCRC) access programme
by: Peter Mugyenyi, et al.
Published: (2006-01-01)

Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre (JCRC) access programme
by: Peter Mugyenyi, et al.
Published: (2006-01-01)

The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
by: Kiwuwa-Muyingo, S, et al.
Published: (2012)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
by: Parikh, S, et al.
Published: (2013)

Opportunities for improving the efficiency of paediatric HIV treatment programmes.
by: Revill, P, et al.
Published: (2015)

HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.
by: Jaganath, D, et al.
Published: (2014)

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
by: Bwakura-Dangarembizi, M, et al.
Published: (2014)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
by: Crook, A, et al.
Published: (2016)

Financial Resource Capacity Development Strategies and Public Secondary School Growth in Kira Municipality, Wakiso District, Uganda
by: Kabuye Rehmah, et al.
Published: (2022-12-01)

Interpretation of the Mwanza and Rakai STD trials
by: Hayes Richard, et al.
Published: (2001-01-01)

Establishing an expert advisory commission to assist the G20’s energy transformation processes
by: Andreas Löschel, et al.
Published: (2017-12-01)

Establishing an expert advisory commission to assist the G20’s energy transformation processes
by: Andreas Löschel, et al.
Published: (2018-03-01)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
by: Kekitiinwa, A, et al.
Published: (2013)

An open-label cluster randomised trial to evaluate the effectiveness of a counselling intervention on linkage to care among HIV-infected patients in Uganda: Study design
by: Eugene Ruzagira, et al.
Published: (2017-03-01)

Das DART-Projekt
by: Harald Rosenbsaum
Published: (2006-01-01)

Validating Dart Model
by: Mazur Jolanta, et al.
Published: (2014-12-01)

Characterization of the DART Impact Ejecta Plume on Dimorphos from LICIACube Observations
by: J. D. P. Deshapriya, et al.
Published: (2023-01-01)